Table of Contents
PITTSBURGH — Mylan Inc. has starting shipping desloratadine tablets (5 mg), an allergy medication, and carbonate extended-release tablets (300 mg), a treatment for manic episodes of bipolar disorder.
The company said Tuesday that both products were released by its Mylan Pharmaceuticals Inc. subsidiary, Mylan said Tuesday.
Mylan’s desloratadine tablets are a generic version of Schering-Plough’s Clarinex allergy medicine, while its carbonate extended-release tablets are a generic version of Noven Therapeutic’s Lithobid tablets.
In the United States, desloratadine tablets (5 mg) had sales of $194.6 million and lithium carbonate ER tablets had sales of about $21 million for the 12 months ended March 31, according to IMS Health figures cited by Mylan.
